Literature DB >> 22059158

How well is Helicobacter pylori treated in usual practice?

Kumaresan Yogeswaran1, Grant Chen, Lawrence Cohen, Mary Anne Cooper, Elaine Yong, Eugene Hsieh, Corwyn Rowsell, Fred Saibil, Jill Tinmouth.   

Abstract

BACKGROUND: Helicobacter pylori is a WHO class I carcinogen also associated with nonmalignant gastrointestinal diseases. Effective treatment exists, and all persons infected with H pylori should receive treatment. However, data regarding the rates of treatment prescription in clinical practice are lacking.
OBJECTIVE: To determine the rates of H pylori treatment in usual practice.
METHODS: Patients with histological evidence of H pylori infection between January 1, 2007, and December 31, 2007, at Sunnybrook Health Sciences Centre (Toronto, Ontario) were identified. Charts were reviewed to determine the rates of H pylori treatment and confirmation of eradication, when indicated. Questionnaires were subsequently sent to endoscopists of patients identified as not having received treatment to determine the reasons for lack of treatment.
RESULTS: A total of 102 patients were H pylori positive and were appropriate candidates for treatment, of whom 58 (57%) were male and 78 (76%) were outpatients, with 92 (90%) receiving eradication therapy. When indicated, 15 of 22 (68%) patients received confirmation of eradication, 13 of 18 (72%) patients underwent repeat endoscopy and 86% received complete therapy. Outpatients were more likely to receive eradication therapy (OR 10.3 [95% CI 2.6 to 40.4]; P=0.001) and complete therapy (OR 13.2 [95% CI 3.8 to 45.7]; P=0.0001) compared with inpatients. Having a follow-up appointment resulted in higher treatment rates (OR 12.0 [95% CI 3.0 to 47.5]; P=0.001).
CONCLUSION: During the time period studied, adequate rates of H pylori treatment were achieved in outpatients and patients who had formal follow-up at Sunnybrook Health Sciences Centre. However, some aspects of care remain suboptimal including treatment of inpatients and care following treatment. Additional studies are required to identify strategies to improve the care of patients infected with H pylori.

Entities:  

Mesh:

Year:  2011        PMID: 22059158      PMCID: PMC3206554          DOI: 10.1155/2011/647904

Source DB:  PubMed          Journal:  Can J Gastroenterol        ISSN: 0835-7900            Impact factor:   3.522


  17 in total

1.  Cost-effectiveness of endoscopic surveillance of gastric ulcers to improve survival.

Authors:  Jennifer M Yeh; Wendy Ho; Chin Hur
Journal:  Gastrointest Endosc       Date:  2010-04-28       Impact factor: 9.427

2.  Influence of the NIH Consensus Conference on Helicobacter pylori on physician prescribing among a Medicaid population.

Authors:  M Thamer; N F Ray; S C Henderson; C S Rinehart; C R Sherman; J H Ferguson
Journal:  Med Care       Date:  1998-05       Impact factor: 2.983

3.  Precancerous lesions of the stomach.

Authors:  S Yamagata; S Hisamichi
Journal:  World J Surg       Date:  1979-11       Impact factor: 3.352

4.  Detection of gastric cancer by repeat endoscopy within a short time after negative examination.

Authors:  O Hosokawa; K Watanabe; M Hatorri; K Douden; H Hayashi; Y Kaizaki
Journal:  Endoscopy       Date:  2001-04       Impact factor: 10.093

5.  Diagnosis and treatment of Helicobacter pylori infection among California Medicare patients.

Authors:  J Roll; A Weng; J Newman
Journal:  Arch Intern Med       Date:  1997-05-12

Review 6.  Recent developments in the epidemiology of Helicobacter pylori.

Authors:  J E Everhart
Journal:  Gastroenterol Clin North Am       Date:  2000-09       Impact factor: 3.806

7.  Application of Maastricht 2-2000 guidelines for the management of Helicobacter pylori among specialists and primary care physicians in israel: are we missing the malignant potential of Helicobacter pylori?

Authors:  Haim Shirin; Shlomo Birkenfeld; Orit Shevah; Arie Levine; Julia Epstein; Mona Boaz; Yaron Niv; Yona Avni
Journal:  J Clin Gastroenterol       Date:  2004-04       Impact factor: 3.062

Review 8.  Eradication therapy in Helicobacter pylori positive peptic ulcer disease: systematic review and economic analysis.

Authors:  Alexander C Ford; Brendan C Delaney; David Forman; Paul Moayyedi
Journal:  Am J Gastroenterol       Date:  2004-09       Impact factor: 10.864

9.  Screening for Helicobacter pylori and nonsteroidal anti-inflammatory drug use in medicare patients hospitalized with peptic ulcer disease.

Authors:  H M Hood; C Wark; P A Burgess; D Nicewander; M W Scott
Journal:  Arch Intern Med       Date:  1999-01-25

Review 10.  The treatment of Helicobacter pylori infection in the management of peptic ulcer disease.

Authors:  J H Walsh; W L Peterson
Journal:  N Engl J Med       Date:  1995-10-12       Impact factor: 91.245

View more
  5 in total

1.  Helicobacter pylori treatment in the hospital setting: a potential model for developing quality improvement initiatives to prevent missed test results.

Authors:  Nicola Jones
Journal:  Can J Gastroenterol       Date:  2011-10       Impact factor: 3.522

2.  Do we eradicate Helicobacter pylori in hospitalized patients with peptic ulcer disease?

Authors:  Frank Wong; George Ou; Sigrid Svarta; Ricky Kwok; Kieran Donaldson; Joe Frenette; Robert Enns
Journal:  Can J Gastroenterol       Date:  2013-09-13       Impact factor: 3.522

3.  Low Rates of Retesting for Eradication of Helicobacter pylori Infection After Treatment in the Veterans Health Administration.

Authors:  Shria Kumar; David C Metz; David E Kaplan; David S Goldberg
Journal:  Clin Gastroenterol Hepatol       Date:  2020-04-06       Impact factor: 11.382

4.  The effect of probiotics supplementation on Helicobacter pylori eradication rates and side effects during eradication therapy: a meta-analysis.

Authors:  Yini Dang; Jan D Reinhardt; Xiaoying Zhou; Guoxin Zhang
Journal:  PLoS One       Date:  2014-11-03       Impact factor: 3.240

5.  Effects of patient age and choice of antisecretory agent on success of eradication therapy for Helicobacter pylori infection.

Authors:  Toshihiro Nishizawa; Hidekazu Suzuki; Ai Fujimoto; Hiroto Kinoshita; Shuntaro Yoshida; Yoshihiro Isomura; Akira Toyoshima; Takanori Kanai; Naohisa Yahagi; Osamu Toyoshima
Journal:  J Clin Biochem Nutr       Date:  2017-02-16       Impact factor: 3.114

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.